Net Income

A new report reveals Gen Z women are rejecting old labels and hustle culture, prioritizing mental health, authentic living, and tech on their own terms.

Genesis Land Development saw record revenues in 2025, but a drop in new orders and a cautious outlook reveal a strategy for a cooling Calgary market.

The Canadian energy firm posted a 12% production jump in 2025, fueled by exploration wins and a major shift to long-life secondary recovery projects.

From Cairo to Hollywood, NYFA alumni and faculty are behind Oscar-nominated films and four international submissions, cementing the school's global impact.

Advantage Energy posts record 2025 results, slashing debt while boosting output and pioneering a major carbon capture project. What's next for the firm?

Ero Copper reports record 2025 production and soaring profits, yet a planned slow start to 2026 has investors weighing near-term hurdles against long-term growth.

After its public debut, BBOT unveils exciting early data from three unique cancer drugs, including a first in pancreatic cancer, backed by a strong cash runway.

The toy giant's new $400M debt offering isn't just about paying bills; it's a strategic move to extend its financial runway and invest in its future.

Digital accessibility leader AudioEye reports record 2025 earnings and unveils a next-gen platform promising enhanced legal protection for businesses.

OFS Credit's net asset value dropped 20% from market volatility, forcing a dividend cut. Can its strategic moves stabilize the ship for investors?

aTyr Pharma heads to a crucial FDA meeting for its lung drug efzofitimod, which missed its main goal but showed significant patient quality-of-life gains.

Major deals with Cadillac and Ferrari mark a pivotal year for Research Frontiers, but can its smart glass tech overcome growing financial losses?

Weebit Nano's advanced memory is at the heart of a South Korean national program aiming to revolutionize AI with ultra-low-power compute-in-memory chips.

As Galapagos pivots its strategy, it brings in a new HR chief to build the high-performing culture crucial for its next chapter of innovation.

As CEO Corie Barry prepares for a key UBS conference, investors seek clarity on Best Buy's strategy for growth amid soft sales and a shifting retail landscape.

As Hyperfine preps its 2025 results, investors and clinicians watch to see if its portable Swoop MRI can translate clinical promise into financial success.

NextCure accelerates its high-stakes ovarian cancer drug trial, but with cash dwindling, can it reach the finish line before time runs out?

Inuvo's stock faces uncertainty as a strategic pivot causes a steep Q4 revenue drop, betting its future on its privacy-focused IntentKey AI technology.

The smart baby monitor firm posts a record $105.7M in 2025 revenue and positive adjusted EBITDA, but a significant net loss raises questions.

With a strong cash position, ArriVent pushes its lead lung cancer drug toward a mid-2026 data readout while building a new pipeline in ADCs.